Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Thursday session in red amid volatile trading. The shares closed down -0.90 points or -1.65% at $53.50 with 6.79 million shares getting traded. Post opening the session at $54.20, the shares hit an intraday low of $53.14 and an intraday high of $54.47 and the price vacillated in this range throughout the day. The 52-week high of (TEVA) is $72.31 and the 52-week low is $52.62. The company has a market cap of $53.83 billion and the numbers of outstanding shares have been calculated to be 1.02 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) on March 23, 2016 announced that the U.S. Food and Drug Administration (FDA) has approved CINQAIR® (reslizumab) Injection, an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
CINQAIR® is administered by intravenous (IV) infusion at a weight-based dose of 3 mg/kg once every four weeks. The treatment is expected to become commercially available to patients, by prescription, during the second quarter of 2016.
“Despite ongoing treatment with today’s standard of care, many patients with severe asthma remain inadequately controlled, the implications of which can lead to increased exacerbations and hospitalization,” said Professor Mario Castro, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine and lead investigator. “The approval of CINQAIR® marks an important advancement in the treatment paradigm for asthma as the therapy has demonstrated significant improvement in multiple measures of asthma control. As a practicing physician, I look forward to the opportunity to provide my patients, who have severe uncontrolled asthma and fit the profile for CINQAIR®, with an option that has the potential to help them achieve control of their disease.”
Shares of Opko Health Inc. (NYSE:OPK) ended Thursday session in green amid volatile trading. The shares closed up +0.50 points or 5.05% at $10.40 with 6.92 million shares getting traded. Post opening the session at $9.96, the shares hit an intraday low of $9.86 and an intraday high of $10.56 and the price vacillated in this range throughout the day. The 52-week high of (OPK) is $19.20 and the 52-week low is $7.12. The company has a market cap of $5.08 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) on March 28, 2016 announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.
Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.
“Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.
Shares of Johnson & Johnson (NYSE:JNJ) ended Thursday session in red amid volatile trading. The shares closed down -0.79 points or -0.72% at $108.19 with 8.17 million shares getting traded. Post opening the session at $108.86, the shares hit an intraday low of $108.04 and an intraday high of $108.98 and the price vacillated in this range throughout the day. The 52-week high of (JNJ) is $109.56 and the 52-week low is $81.79. The company has a market cap of $297.99 billion and the numbers of outstanding shares have been calculated to be 2.76 billion shares.
Johnson & Johnson (JNJ) on March 28, 2016 announced that it will webcast Annual Meeting of Shareholders at 10:00 a.m. (EDT) on Thursday, April 28, 2016, from the State Theatre in New Brunswick, N.J.
Investors and other interested parties may access a live video webcast of the meeting by visiting the company’s website at www.jnj.com and clicking on the webcast icon.
A replay of presentations from the meeting will be made available approximately two hours after the live meeting concludes. The webcast replay will remain available for three months following the meeting and can be accessed by clicking on “Webcasts & Presentations” in the Investor Relations section of the company’s website. Interested parties can also follow the meeting on Twitter using #JNJASM16.